TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06556056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SesZen-Bio Serum
Description: Mode of Usage: Dispense a small amount of serum directly onto your fingertips and gently massage it into the roots and scalp using circular motions to ensure even distribution and absorption. Continue this process across your entire scalp, focusing on areas that need the most attention. Avoid rinsing the serum out; instead, allow it to absorb fully.~Dosage form: Liduid Frequency: Daily Night application. Route of administration: Topical

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Minoxidil hair serum (1%)
Description: Mode of Usage: Dispense a small amount of serum directly onto your fingertips and gently massage it into the roots and scalp using circular motions to ensure even distribution and absorption. Continue this process across your entire scalp, focusing on areas that need the most attention. Avoid rinsing the serum out; instead, allow it to absorb fully.~Dosage form: Liquid Frequency: Daily Night Application Route of administration: Topical

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mode of Usage: Dispense a small amount of serum directly onto your fingertips and gently massage it into the roots and scalp using circular motions to ensure even distribution and absorption. Continue this process across your entire scalp, focusing on areas that need the most attention. Avoid rinsing the serum out; instead, allow it to absorb fully.~Dosage form: Liquid Frequency: Daily Night Application Route of administration: Topical
Study: NCT05765851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1103a
Description: One IV infusion Q3W on Day 1 of each 21-day cycle
Study: NCT06284122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: when associated to bendamustin IV 375mg/m² SC 1400 mg allowed from C2 Day 1 of C1 Day 1 from C2 to C6 Day 1 from C7 to C18

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obinutuzumab
Description: when associated to bendamustin 1000 mg Day 1, Day 8, Day 15 of C1 Day 1 from C2 to C8 Day 1 from C9 to C20

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustin
Description: 90 mg/m2 Day 1 and Day 2 from C1 to C6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustin
Description: 90 mg/m2 Day 1 and Day 2 from C1 to C6
Study: NCT06478758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: The ibuprofen group (n=36) was administered 800 mg of ibuprofen . All procedures were performed with the same team. During surgery, a 20% increase in the participant's heart rate and mean arterial pressure remifentanil infusion was administered. During the postoperative period, all participants continued to receive acetaminophen at 8-hour intervals, and tramadol was given to those with a visual analog score above 4. In the recovery room, the participants with a visual analog score of \> 4 were administered 100 mg of tramadol. All participants were prescribed acetaminophen every 8 hours postoperatively in whilst on the ward. Participants with a visual analog score of \> 4 received rescue analgesia with 100 mg of tramadol. Visual analog score and vital parameters were recorded at 1, 2, 6, 12 and 24 h postoperatively. The incidence of nausea and vomiting during the 24 h postoperative period was also recorded.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 100 MG/ML
Description: The investigators administered 1000 mg of acetaminophen to the participants in Group A. A 20% increase in the participant's heart rate and mean arterial pressure was evaluated as pain and remifentanil infusion was administered. All participants continued to receive the routine application of acetaminophen at 8-hour intervals, and tramadol was given to those with a visual analog score above 4, postoperatively.In the recovery room, participants with a visual analog score of \> 4 were administered 100 mg of tramadol. All participants were prescribed acetaminophen every 8 hours postoperatively in whilst on the ward. Participants with a visual analog score of \> 4 received rescue analgesia with 100 mg of tramadol. Visual analog score and vital parameters were recorded at 1, 2, 6, 12 and 24 h postoperatively. The incidence of nausea and vomiting during the 24 h postoperative period was also recorded.
Study: NCT06459778

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Piezo-ICSI
Description: Participants had their oocytes cohort divided, where half were injected using conventional ICSI and the other half were injected using Piezo-ICSI.
Study: NCT05196620

Intervention type: OTHER
Intervention: Endoanal Ultrasound (EAUS)
Description: Endoanal Ultrasound pre- and postpartum
Study: NCT05838248

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: antibiotic duration
Description: Duration of antibiotic treatment post appendectomy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: antibiotic duration
Description: Duration of antibiotic treatment post appendectomy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: antibiotic duration
Description: Duration of antibiotic treatment post appendectomy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: antibiotic duration
Description: Duration of antibiotic treatment post appendectomy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: antibiotic duration
Description: Duration of antibiotic treatment post appendectomy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: antibiotic duration
Description: Duration of antibiotic treatment post appendectomy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: antibiotic duration
Description: Duration of antibiotic treatment post appendectomy
Study: NCT04341194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-driven pain management with skin-to-skin contact
Description: The infant is placed naked (except for a diaper and possibly a hat) on the parents' bare chest.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-driven pain management with skin-to-skin contact/breastfeeding/parental singing
Description: Live parental infant-directed lullaby singing is an individually tailored, non-verbal, multisensory, multimodal and affective tool to regulate the infant before, during and after venipuncture. Direct breast-feeding has demonstrated efficacy that is equal to, or greater than, sweet taste interventions in reducing behavioral and physiological responses to pain in full-term infants undergoing venipuncture with no demonstrated adverse outcomes. Direct breast-feeding should be considered the preferred first-line analgesic intervention for painful procedures performed on full-term infants.
Study: NCT04883580

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Navigation and Positioning System for Orthopedic Surgeries
Description: Experimental group: orthopedic surgery navigation system (Tuodao) assisted pedicle screw fixation~Control group: orthopedic surgery navigation system (tianzhihang) assisted pedicle screw fixation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navigation and Positioning System for Orthopedic Surgeries
Description: Experimental group: orthopedic surgery navigation system (Tuodao) assisted pedicle screw fixation~Control group: orthopedic surgery navigation system (tianzhihang) assisted pedicle screw fixation
Study: NCT06295081

Intervention type: OTHER
Intervention: Exercise exposure
Description: Exercise is NOT part of our study protocol. Participants will voluntarily participate in a mass-participation exercise event (i.e. walking, cycling or running). Participation in this exercise event is voluntary and independent from participation in this study (i.e. participants would also take part in the exercise event if they did not participate in our study). Therefore, we do not consider the performed exercise an intervention or part of our study protocol. Hence, we consider our study design to be observational.~Participants will perform exercise during a mass-participation exercise event, stratified for type of exercise (walking versus running versus cycling; n=500 each).~The mass-participation exercise events have a sport-specific minimum distance of:~a mass-participation exercise event with a:~* Walking distance ≥20 km~* Cycling distance ≥100 km~* Running distance ≥15 km

Intervention type: OTHER
Intervention: Exercise exposure
Description: Exercise is NOT part of our study protocol. Participants will voluntarily participate in a mass-participation exercise event (i.e. walking, cycling or running). Participation in this exercise event is voluntary and independent from participation in this study (i.e. participants would also take part in the exercise event if they did not participate in our study). Therefore, we do not consider the performed exercise an intervention or part of our study protocol. Hence, we consider our study design to be observational.~Participants will perform exercise during a mass-participation exercise event, stratified for type of exercise (walking versus running versus cycling; n=500 each).~The mass-participation exercise events have a sport-specific minimum distance of:~a mass-participation exercise event with a:~* Walking distance ≥20 km~* Cycling distance ≥100 km~* Running distance ≥15 km

Intervention type: OTHER
Intervention: Exercise exposure
Description: Exercise is NOT part of our study protocol. Participants will voluntarily participate in a mass-participation exercise event (i.e. walking, cycling or running). Participation in this exercise event is voluntary and independent from participation in this study (i.e. participants would also take part in the exercise event if they did not participate in our study). Therefore, we do not consider the performed exercise an intervention or part of our study protocol. Hence, we consider our study design to be observational.~Participants will perform exercise during a mass-participation exercise event, stratified for type of exercise (walking versus running versus cycling; n=500 each).~The mass-participation exercise events have a sport-specific minimum distance of:~a mass-participation exercise event with a:~* Walking distance ≥20 km~* Cycling distance ≥100 km~* Running distance ≥15 km
Study: NCT05874401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: Participants will receive intravenous trilaciclib infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive intravenous placebo infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topotecan
Description: Participants will receive intravenous topotecan infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Participants will receive intravenous topotecan infusion
Study: NCT05838248

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: antibiotic duration
Description: Duration of antibiotic treatment post appendectomy
Study: NCT05784909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rezum
Description: Technique With the patient in a lithotomy position, after cystoscopy, an RF current is applied to. Water vapour is delivered through a retractable vapor needle via emitter holes in the transurethral device. This is done in 9-second bursts to the transition zone of the prostate, where, via convection, it diffuses evenly throughout the target tissue. The depth of the needle penetrating is approximately 10 mm.~Upon contact with body-temperature tissue, the water vapour then condenses. This phase shift to a liquid state dispenses concentrated energy onto the cell membranes of the target tissue, triggering instant cell necrosis. Overlapping injection sites can be established with repeated applications in order to fully target areas of hypertrophy. Saline flush irrigation is used to both cool the urethra and to promote visualization.~At the end of the procedure Urethral catheter is fixed for 1-3 days.
Study: NCT06554314

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: probiotics
Description: Eat a capsule for once, and once a day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics
Description: Eat a capsule for once, and once a day
Study: NCT05765851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DXd
Description: One IV infusion Q3W on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DXd
Description: One IV infusion Q3W on Day 1 of each 21-day cycle
Study: NCT05819801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-fasting
Description: Instructing patients to eat before their local-only procedure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fasting
Description: Instructing patients to fast before their local-only procedure
Study: NCT06493253

Intervention type: DIAGNOSTIC_TEST
Intervention: Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)
Description: Biomarker name: FibroNest Phenotypic Fibrosis Composite Score Acronym: FibroNest Ph- FCS Type of Biomarker: Histologic based, Digital, Quantitative Image Analysis, Imaging modality Definition: A quantitative, normalized (no unit) and continuous composite

Intervention type: DIAGNOSTIC_TEST
Intervention: Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)
Description: Biomarker name: FibroNest Phenotypic Fibrosis Composite Score Acronym: FibroNest Ph- FCS Type of Biomarker: Histologic based, Digital, Quantitative Image Analysis, Imaging modality Definition: A quantitative, normalized (no unit) and continuous composite
Study: NCT05450029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 6 cycles of mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) followed by long course chemoradiotherapy (50 Gy in 25 fractions) followed by surgery. Patients will receive sintilimab 3mg/kg every 2 weeks during chemoradiotherapy (2nd-6th cycle).
Study: NCT05603442

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic intervertebral foramen block
Description: The thoracic intervertebral foramen block is performed by placing the needle tip over and behind the transverse process of vertebra, via the thoracic intervertebral foramen.
Study: NCT05962775

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ethanol Sclerotherapy for Endometrioma
Description: 2 gr IV cefazolin sodium will be administered 30 minutes before the procedure. The endometrioma cyst content will be aspirated by a single lumen needle, and the total aspirated volume calculation will be done. The endometrioma will then be washed with saline until the color of the cyst content becomes clear. Then, 96% ethanol will be injected into the cyst. The volume of injected ethanol will be 60% of the first aspirated volume (maximum 100 ml). After 10 minutes all ethanol will be aspirated.
Study: NCT06258382

Intervention type: OTHER
Intervention: Questionnaires and functional test
Description: Data will be collected from different sources. Questinnaires, Medical journal, Obstetrical records and functional tests

Intervention type: OTHER
Intervention: Questionnaires and functional test
Description: Data will be collected from different sources. Questinnaires, Medical journal, Obstetrical records and functional tests
Study: NCT04808635

Intervention type: OTHER
Intervention: no intervention, this is a cross sectional questionnaire based study.
Description: no intervention, this is an observational cross sectional study

Intervention type: OTHER
Intervention: no intervention, this is a cross sectional questionnaire based study.
Description: no intervention, this is an observational cross sectional study
Study: NCT05511753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: Insert stainless steel needles into the above acupoints and twist the needles to get qi. In addition, electroacupuncture stimulation (intensity 1mA, frequency 2Hz) was applied to connect the ipsilateral Yifeng and Wangu, and the ipsilateral Zhongzhu and Quchi.
Study: NCT05531851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization
Description: For IASTM treatment, IASTM soft tissue mobilization blade to apply the treatment used. It is a stainless steel shaped metal tool with beveled edges. The researcher, with a 30° angled tool, at a speed of 120 BPM, in the direction of the fibers of the m.biceps brachii muscle.~He applied it with a light pressure by intervening with his weight. Researcher during treatment used a metronome to ensure consistent speed and adjusted the instrument angle before each subject's treatment.~calibrated with a protractor. The application took 8 minutes and the instrument was comfortable on the skin.
Study: NCT05790707

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation ablation + antiarrhythmic drugs
Description: Atrial fibrillation ablation will be performed with endovascular catheters and will be done either with radiofrequency, cryoballoon or pulsed field ablation.~Amiodarone, flecainide, sotalol, propafenone are the anti arrhythmic drugs allowed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiarrhythmic drug
Description: Amiodarone, flecainide, sotalol, propafenone are the anti arrhythmic drugs allowed.
Study: NCT04782752

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation: Varying Doses of RT
Description: 3+3 radiation dose escalation model to see the maximum tolerated dose
Study: NCT05739734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRIS100
Description: local application of CRIS100
Study: NCT04661449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive lifestyle intervention
Description: Feeding guidance: promoting exclusive breastfeeding and healthy diet (Pediatrician). Motor development assessment and guidance: Alberta Infant movement scale (AIMS) evaluation, guidance for motor development (Rehabilitation Therapist). Healthcare education: improvement of environmental exposure (Pediatrician).
Study: NCT06429514

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ganoderma lucidum spore powder
Description: One bag at a time, 2 times a day, 2g / bag

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: One bag at a time, 2 times a day, 2g / bag
Study: NCT05622994

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rimonabant
Description: Rimonabant 5mg per day is administered for 90 days. The comparator is placebo for the same duration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rimonabant
Description: Rimonabant 5mg per day is administered for 90 days. The comparator is placebo for the same duration.
Study: NCT05140317

Intervention type: PROCEDURE
Intervention: Transcatheter heart valve implantation with or withour predilatatation
Description: long term up to 5 years echographic and clinical follow up

Intervention type: PROCEDURE
Intervention: Transcatheter heart valve implantation with or withour predilatatation
Description: long term up to 5 years echographic and clinical follow up
Study: NCT06474481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib, 160mg PO BID.on days 1-28 Induction treatment: 4-6cycles ; Maintenance: 1 year;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Induction treatment: Obinutuzumab (G), 1000mg, IV, D1/8/15 (C1), D1 (C2-4/6); for 4-6 cycles, 1 cycle = 28 days Maintenance: Obinutuzumab (G), 1000mg, IV, every 2 months for 1 year;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone (P), 100 mg, PO, D2-6；for 4-6 cycles for CHOP treatment , 1 cycle = 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (C), 750 mg/m2, IV, D2; for 4-6 cycles for CHOP treatment , 1 cycle = 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine (O), 1.4 mg/m2 (maximum 2 mg), IV, D2; for 4-6 cycles for CHOP treatment , 1 cycle = 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin (H), 50 mg/m2, IV, D2; for 4-6 cycles for CHOP treatment ，1 cycle = 28 days
Study: NCT06388109

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive Peers mobile app
Description: Positive Peers is a multifunctional mobile app using a mind, body, spirit theme aimed to improve HIV care outcomes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive Peers mobile app
Description: Positive Peers is a multifunctional mobile app using a mind, body, spirit theme aimed to improve HIV care outcomes.
Study: NCT06096428

Intervention type: DEVICE
Intervention: Pulsed-field ablation
Description: Pulsed-field ablation will be done using pentaspline catheter (Farawave, Boston Scientific) and pulsed-field energy generator. The goal will be achieve of electrical isolation of pulmonary veins.

Intervention type: DEVICE
Intervention: Radiofrequency ablation
Description: Pulmonary vein isolation will be done using radiofrequency catheter (Qdot, Biosense-Webster) and generator of radiofrequency energy (nGEN, Biosense-Webster).
Study: NCT05407519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab + Sitravatinib
Description: Drug: Tislelizumab Tislelizumab 200mg IV q3w Other Names: BGB-A317, Immunotherapy, Anti-PD-1 antibody Drug: Sitravatinib Sitravatinib 100mg PO qd Other Name: tyrosine kinase inhibitor, TKI
Study: NCT03807102

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Vaccine
Description: NeoAntigen Tumor Vaccine (5 injections for each 3 days and then 1 injection for each 3 months till recurrence or up to 2 years).
Study: NCT06518837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: The intervention aims to assess the feasibility, safety, and efficacy of tirzepatide for weight loss in patients with early-stage hormone receptor-positive, HER2-negative breast cancer, potentially improving treatment outcomes and overall health.
Study: NCT00104754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal SN-38
Study: NCT04313335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Oral Duloxetine (up to 60 mg per day) will be given, titrated, tapered in accordance with the pain intensity during the acute herpes zoster period.
Study: NCT06258382

Intervention type: OTHER
Intervention: Questionnaires and functional test
Description: Data will be collected from different sources. Questinnaires, Medical journal, Obstetrical records and functional tests
Study: NCT05990660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JuxtaFlow System
Description: Mild, controlled negative pressure introduced into the renal pelvis via JuxtaFlow catheters
Study: NCT06554938

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: water pik
Description: One side of the mouth was flossed with Super Floss® (Oral-B) and the other with Waterpik®.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Super floss
Description: One side of the mouth was flossed with Super Floss® (Oral-B) and the other with Waterpik®.